Product Description
Novartis is developing Vildagliptin as a treatment for Type 2 Diabetes Mellitus. (Sourced from: https://www.novartis.com/sg-en/sites/novartis_sg/files/Galvus-Jul2020.SIN-App051120.pdf)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Mexico
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VME-005-22 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-10-01 |
|
| SIL-30013-III-20(1) | P3 |
Recruiting |
Type 2 Diabetes |
2024-03-01 |
63% |
| SIL-30013-III-20(1) | P3 |
Recruiting |
Type 2 Diabetes |
2024-03-01 |
63% |
| CTR20222912 | P1 |
Completed |
Type 2 Diabetes |
2023-10-15 |
|
| CTR20223040 | P1 |
Completed |
Type 2 Diabetes |
2023-04-21 |